510(k) K223597
K223597 is an FDA 510(k) premarket notification submitted by 23AndMe, Inc. for the device "23andMe® Personal Genome Service® (PGS®) Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants)". The FDA issued a decision of Substantially Equivalent on August 31, 2023. The device falls under product code QAZ (Cancer Predisposition Risk Assessment System), a Class II device regulated under 21 CFR 866.6090. 23AndMe, Inc. has at least 8 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- August 31, 2023
- Date Received
- December 2, 2022
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Cancer Predisposition Risk Assessment System
- Device Class
- Class II
- Regulation Number
- 866.6090
- Review Panel
- PA
- Submission Type
A qualitative in vitro molecular diagnostic system used for the detection of select variants in specified cancer-related genes. The device is intended to be used on genomic DNA isolated from human specimens collected by the user. The results of the test provide users with a genetic health risk assessment for developing certain cancers. The test may not include all variants associated with a predisposition of developing cancer and is not intended to describe a persons overall risk of developing any type of cancer nor to aid in determination of treatment or act as a substitute for recommended cancer screenings or appropriate follow-up. The device is for over-the-counter use.